Why Is VERA THERAPEUTICS IN A (VERA) Stock Moving Today?

Why VERA stock is down today

VERA stock is down 6.06% at $31.63 as of the latest update. The decline follows a volatile intraday session marked by early strength and a sharp reversal. The stock opened at $33.75 but failed to sustain momentum, reaching a high of $34.00 shortly after the market opened before falling to a session low of $31.60. The drop comes after a series of positive developments around the company's Trutakna drug, including positive Phase 3 trial results and continued analyst optimism, but appears to reflect investor caution and profit-taking.

What Happened

Vera Therapeutics announced that its Trutakna drug met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 IgA nephropathy trial. This milestone led to a 13% rise in the stock earlier in the week. The company also presented at the Morgan Stanley 24th Annual Global Healthcare Conference, where executives detailed the drug’s progress. Analysts from Raymond James and TD Cowen reiterated positive ratings, with Raymond James maintaining a Strong Buy and TD Cowen a Buy. Despite these developments, the stock has seen a reversal in sentiment, with investors taking profits after a recent rally.

What The Data Shows

The stock opened higher but has since reversed course, trading at $31.60 with a volume of 1.1 million shares, which is 0.6 times the 3-month daily average. The stock is currently trading within its 52-week range of $22.72 to $56.05 and has declined 4.6% over the past eight sessions. Options activity has been skewed to the put side, with $11.3 million in put premiums versus $0 in call premiums, and the largest single print at $5.6 million. Additionally, the CEO, Marshall Fordyce, has sold shares on three separate occasions in the last 90 days, totaling $3.3 million.

What To Watch

Investors should monitor the FDA's review process for Trutakna, as well as any further analyst commentary or corporate updates. The stock is currently unprofitable with an EPS of -5.89 and a market cap of $2.5 billion.